Collins Helen Louise 4

What Happened
Helen Louise Collins, a director of Kura Oncology (KURA), was granted a 35,000-share derivative award (reported as an option) on June 4, 2026. The Form 4 reports the acquisition at $0.00 (total reported cash = $0), and a footnote states the option vests in full on the one-year anniversary of the grant. This is a compensation grant to a director rather than a purchase or sale in the open market.

Key Details

• Transaction date: 2026-06-04 (reported on Form 4 filed same day).
• Transaction type/code: A — Grant/award (derivative option).
• Shares/options granted: 35,000; reported price per share: $0.00; reported cash paid: $0.
• Vesting: Option vests in full one year after the grant date (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Timeliness: Filing appears timely (filed same day as the transaction).
• No 10b5-1 plan, tax withholding, or sale noted in this filing.

Context
This is a typical director compensation award and does not represent an open-market purchase or sale. As a derivative (option) the grant must vest and, if applicable, be exercised before resulting in ownership of common shares. Such grants are common for aligning directors’ interests with shareholders but should not be interpreted alone as a directional market signal.